A Phase 2 interventional study of CM310 in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-08-20.
Sponsored by Keymed Biosciences Co.Ltd · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 12 studies testing stapokibart in Dermatitis, Atopic — 2 open to participants now, 3 under way, 3 of them phase 3. stapokibart · Dermatitis, Atopic.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, this one is the 2nd largest by enrollment, is one of 3 that started in 2023, is one of 5 in phase 2, and was the 7th registered.
1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.
Browse Dermatitis, Atopic studies →2 of the 12 studies testing stapokibart in Dermatitis, Atopic are open now, in 1 country. Recruiting first, the newest first:
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–12
Keymed Biosciences Co.Ltd · Sites in China
Ages 2–11
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
12 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 7 · Phase 3 5
First in 2020; this study’s year is marked. 3 started in 2023.
This study's enrollment of 263 is above the median of 82 across 1,248 interventional studies indexed under Dermatitis, Atopic.
Median enrollment 170 across the 12 interventional studies. Of the 9 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
12 of 12 have an industry lead sponsor. The 1 most frequent:
Keymed Biosciences Co.Ltd is the lead sponsor of 68 studies on the registry; 34 are open to participants now.
18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd: 4 open now, 5 under way, 3 of them phase 3. Of 10 finished, 0 (0%) have results posted.
Among the 18 studies in Dermatitis, Atopic by Keymed Biosciences Co.Ltd, this one is the 2nd largest by enrollment, is one of 4 that started in 2023, is one of 9 in phase 2, and was the 10th registered.
Keymed Biosciences Co.Ltd’s Dermatitis, Atopic studies by the year they started, since 2020.
1 of the studies testing stapokibart in Dermatitis, Atopic that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07106372Phase 3Keymed Biosciences Co.LtdA Study of Stapokibatrt in Children Subjects With Atopic Dermatitis | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 12 studies testing stapokibart in Dermatitis, Atopic, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Keymed Biosciences Co.Ltd’s 18 in Dermatitis, Atopic:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.
The study consists of an screening period, treatment period, and safety follow-up period.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biological: CM310
CM310, subcutaneous injection
Adverse events (AEs)
Incidence of adverse events (AEs).
Time frame: up to Week 60
Percentage of subjects achieving an Investigator's Global Assessment (IGA) score of 0 at each scheduled assessment visit
Time frame: up to Week 60
Percentage of subjects achieving an Investigator's Global Assessment (IGA) score of 1 at each scheduled assessment visit
Time frame: up to Week 60
Percentage of subjects achieving ≥75% improvement from baseline in the Eczema Area and Severity Index (EASI-75) at each scheduled assessment visit
Time frame: up to Week 60
Percentage of subjects achieving ≥90% improvement from baseline in the Eczema Area and Severity Index (EASI-90) at each scheduled assessment visit
Time frame: up to Week 60
Change from baseline in Eczema Area and Severity Index (EASI) score at each scheduled assessment visit
Time frame: up to Week 60
Percentage change from baseline in Eczema Area and Severity Index (EASI) score at each scheduled assessment visit
Time frame: up to Week 60
Change and percentage change from baseline in Eczema Area and Severity Index (EASI) score at each scheduled assessment visit
Time frame: up to Week 60
Percentage of subjects achieving a ≥4-point reduction from baseline in the weekly mean of daily Peak Pruritus Numerical Rating Scale (PP-NRS) scores
Time frame: up to Week 60
Percentage of subjects achieving a ≥3-point reduction from baseline in the weekly mean of daily Peak Pruritus Numerical Rating Scale (PP-NRS) scores
Time frame: up to Week 60
Change and percentage change from baseline in the weekly mean of daily Peak Pruritus Numerical Rating Scale (PP-NRS) scores
Time frame: up to Week 60
Change and percentage change from baseline in the body surface area (BSA) affected by atopic dermatitis (AD) at each scheduled assessment visit
Time frame: up to Week 60
Change from baseline in Dermatology Life Quality Index (DLQI) score at each scheduled assessment visit
Time frame: up to Week 60
Trough concentration (Ctrough) of CM310
Time frame: up to Week 60
Incidence of treatment-emergent anti-drug antibodies (ADA)
Time frame: up to Week 60
Incidence of neutralizing antibodies (NAb)
Time frame: up to Week 60
Ran from Dec 2023 to primary completion in Nov 2025, 23 months.
Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 23 months is above that.
Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Stapokibart